Centriole Amplification Independently from Aurora A Overexpression Causes Resistance to Alisertib Treatment
PublicDownloadable Content
open in viewerAcute Myeloid Leukemia (AML) is a cancer of overproliferative blood cells and is the most common type of blood cancer to occur in adults. AML patients are commonly treated with chemotherapeutic approaches. Currently, the identification and development of therapies that specifically or preferentially impact growth of leukemia cells is in high demand. Our studies have focused on exploring the molecular effects of Aurora A inhibition, and investigating cellular biomarkers, in addition to Aurora A levels, that may predict drug sensitivity in AML patients. Our initial correlative studies on AML cell lines, does not show a clear correlation between Aurora A levels and Alisertib sensitivity. Instead, they suggest that an increased centriole number confers resistance of AML cells to Alisertib.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Creator
- Publisher
- Identifier
- E-project-042617-232556
- Advisor
- Year
- 2017
- Date created
- 2017-04-26
- Resource type
- Major
- Rights statement
Relations
- In Collection:
Items
Permanent link to this page: https://digital.wpi.edu/show/gf06g4373